maritide vs retatrutide Emerging research on metabolic therapies in 2025–2026 show major advances with newer drugs targeting multiple metabolic pathways. Triple-receptor agonists like retatrutide, which act on GLP-1, GIP, and glucagon receptors, are producing some A new weight-loss drug called

Description

Soiza, C

Read more: To view or add a comment, sign in This study supports the safe use of metformin in transplant recipients living with diabetes, demonstrating an association with improved survival and cardiovascular outcomes and graft preservation

Moderna included the requested analyses in its submission, including data from a separate phase 3 trial comparing mRNA-1010 with a licensed high-dose influenza vaccine

When combined with lifestyle changes and not preceded by body-weight loss due to low-energy diet, daily administration of 3.0 mg of liraglutide provided an additional body-weight loss of 4.05.4% compared with placebo [30,31,32] (Fig